Sarepta Therapeutic (SRPT) Could Be Worth $83-$139/Sh - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Lifts Target on Sarepta Therapeutic (SRPT) to $70, Drug Could Sell for $300-$400K/year
October 4, 2012 3:50 PM EDTIn a note late Wednesday, Wedbush substantially raised its price target Outperform-rated Sarepta Therapeutic (NASDAQ: SRPT) from $26 to $70 following positive results from their Phase IIb extension trial of eteplirsen for Duchenne muscular dystrophy.
Some highlights from the report:
"Importantly, boys... More
Sarepta Therapeutics (SRPT) Surges as Eteplirsen Met the Primary Endpoint
October 3, 2012 7:12 AM EDTShares of Sarepta Therapeutics (Nasdaq: SRPT) are launching 73 percent in pre-open trading Wednesday after the company announced that treatment with its lead exon-skipping compound, eteplirsen, met the primary efficacy endpoint, increase in novel dystrophin, and achieved a significant clinical benefit on the primary clinical outcome, the 6-minute walk test (6MWT) over the placebo/delayed treatment cohort in a Phase IIb extension trial in Duchenne... More
Sarepta (SRPT) Says Eteplirsen Met Primary Endpoint in Phase IIb
October 3, 2012 7:08 AM EDTSarepta Therapeutics (Nasdaq: SRPT), announced that treatment with its lead exon-skipping compound, eteplirsen, met the primary efficacy endpoint, increase in novel dystrophin, and achieved a significant clinical benefit on the primary clinical outcome, the 6-minute walk test (6MWT) over the placebo/delayed treatment cohort in a Phase IIb extension trial in Duchenne muscular dystrophy (DMD) patients.
... More
Sarepta (SRPT) Receives Termination Notice from U.S. DoD for Ebola Program
October 3, 2012 7:07 AM EDTSarepta Therapeutics, Inc. (Nasdaq: SRPT) received notice from the U.S. Department of Defense (DoD) that the Ebola portion of the Company's contract for the advanced development of hemorrhagic fever virus therapeutics was terminated for the convenience of the government due to funding constraints. The DoD's Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded this contract in July 2010 to advance a platform... More
